Enanta Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 28 2017 - 7:30AM
Business Wire
- Presentation and Question and Answer
Session to be Webcast beginning at 4:00 p.m. PT on January 9,
2018
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will make a formal presentation at the 36th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 9, 2018. The
presentation will contain a business overview and an update on
Enanta’s research and development programs. A question and answer
session with investors will follow the presentation.
A live webcast of the presentation, as well as the question and
answer session that follows the presentation, will be accessible by
visiting the “Events and Presentations” section on the “Investors”
page of Enanta’s website at www.enanta.com. A replay of the
webcasts will be available following the presentation and will be
archived for approximately 60 days.
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved in
jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the marketed regimens MAVYRET™(U.S.)
/MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(U.S.) (paritaprevir/ritonavir/ombitasvir/dasabuvir). Royalties and
milestone payments from the AbbVie collaboration are helping to
fund Enanta’s research and development efforts, which are currently
focused on the following disease targets: non-alcoholic
steatohepatitis (NASH)/ primary biliary cholangitis (PBC),
respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Please visit www.enanta.com for more information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171228005016/en/
Investor Contact:Enanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024